FIELD: biotechnology.
SUBSTANCE: in particular, the invention includes an expression vector containing a base sequence encoding two types of short hairpin RNA (shRNA) that inhibit the expression of PD-1 and TIGIT genes that impair T-cell function, and a base sequence encoding a chimeric antigen receptor (CAR) or monoclonal T cell receptor (mTCR), as well as to the T cell containing it. Also disclosed is a pharmaceutical composition containing this T-cell.
EFFECT: invention is effective for treatment of malignant neoplasm.
114 cl, 24 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| MODIFIED IMMUNOREGULATORY ELEMENT AND IMMUNITY CHANGE BY THIS ELEMENT | 2017 |
|
RU2767206C2 |
| ANTIGEN-BINDING PROTEIN RECOGNIZING PEPTIDE ORIGINATING FROM MAGE-A4 | 2018 |
|
RU2777074C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2798348C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| SPECIFIC TO MUCIN-1 POLYPEPTIDE AND ITS USE | 2021 |
|
RU2805840C1 |
| REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
